Delivering Advanced Therapeutics
Presentation of Positive Preclinical Results for CP024 Nasal Growth Hormone
Critical Pharmaceuticals to Present Positive Preclinical Data on Nasal Growth Hormone
Critical Pharmaceuticals, an emerging biotechnology company, will present positive preclinical results from its CP024 program for growth hormone deficiency at the AAPS Annual Meeting in New Orleans (14-18 November) and Marcus Evans Peptide Formulation and Product Development Forum in Vienna (2-3 December). CP024 is a nasal spray of human growth hormone (hGH) developed using Critical Pharmaceuticals proprietary CriticalSorb™ technology and supported by funding from the Wellcome Trust.
“We are delighted to have achieved exceptional bioavailability and tolerability of human growth hormone delivered nasally using our CriticalSorb™ technology ” said Professor Lisbeth Illum, CEO of Critical Pharmaceuticals. “As we move into Phase 1 clinical studies, we look forward to demonstrating the potential of CP024 to provide patients with an attractive alternative to frequent injection of human growth hormone and other complex biological drugs.”
CriticalSorb™ is an absorption promoter that is widely applicable to the non-invasive delivery of not just human growth hormone, but many other biological drugs. CriticalSorb™ is a ‘GRAS’ (generally regarded as safe) material that is already marketed in various drug products for intravenous and oral administration with an excellent safety and tolerability profile in humans.
As well as presenting the latest results on CP024, Professor Lisbeth Illum and Dr Andy Lewis (Director Operations at Critical Pharmaceuticals) will present the latest developments with Critical Pharmaceuticals CriticalSorb™ and CriticalMix™ drug delivery technologies.